Table 5. Multivariate analysis of survival after being diagnosed with intermediate-stage hepatocellular carcinoma.
| Variables | Multivariate analysis | P | |
|---|---|---|---|
| Hazard ratio | 95% CI | ||
| Any patients (n = 105) | |||
| Effectiveness of initial TACE in intermediate stage | |||
| Responder | Reference | ||
| Non-responder | 3.080 | 1.920–4.942 | <0.001 |
| Administration timing of sorafenib | |||
| Conversion before progressing to advanced stage | Reference | ||
| Conversion after progressing to advanced stage | 1.808 | 1.156–2.829 | 0.009 |
| Propensity score matched dataset (n = 72) | |||
| Effectiveness of initial TACE in intermediate stage | |||
| Responder | Reference | ||
| Non-responder | 2.754 | 1.570–4.829 | < 0.001 |
| Administration timing of sorafenib | |||
| Conversion before progressing to advanced stage | Reference | ||
| Conversion after progressing to advanced stage | 1.905 | 1.133–3.203 | 0.015 |
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization.